• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

miR-92a在胃癌中的诊断和预后价值：一项系统评价和荟萃分析。

The diagnostic and prognostic value of miR-92a in gastric cancer: A systematic review and meta-analysis.

作者信息

Guo Hanxu, Wang Yuhang, Wang Zhicheng, Wang Zishu, Xue Sheng

机构信息

Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233000, People's Republic of China.

Department of Urology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233000, People's Republic of China.

出版信息

Open Med (Wars). 2021 Sep 16;16(1):1386-1394. doi: 10.1515/med-2021-0347. eCollection 2021.

DOI:10.1515/med-2021-0347
PMID:34611549
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8447977/
Abstract

BACKGROUND

miR-92a is believed to have a significant role in the diagnosis and prognosis of different types of tumors, but the potential impact of its expression is still controversial due to the sample size. We conducted the meta-analysis to figure out whether miR-92a could be used as a detecting tool for assessing the prognosis of gastric cancer.

METHOD

A literature search was conducted by retrieving the Web of Science, PubMed, EMBASE, Chinese National Knowledge Infrastructure, VIP (Technology of Chongqing databases), and Wanfang databases (last updated by February 2020). The sensitivity (SEN), specificity (SPE), positive and negative likelihood ratios (PLR and NLR), diagnostic odds ratio (DOR), and area under the ROC curve (AUC) were pooled to explore the diagnostic performance of miR-92a. The pooled hazard ratios (HRs) and 95% CIs of miR-92a for overall survival (OS) were calculated to explore the prognostic performance of miR-92a.

RESULTS

Nine articles containing 11 studies were included. The pooled SEN and SPE were 0.76 and 0.79. Besides, the pooled PLR and NLR were 3.7 and 0.30, and the pooled DOR was 12. AUC was 0.84, indicating a significant value of miR-92a in gastric cancer detection. For the prognostic analysis of miR-92a in gastric cancer, the univariate and multivariate data's poor OS were 1.37 and 2.01.

CONCLUSION

The present meta-analysis demonstrated that miR-92a could be a potential biomarker for the detection of gastric cancer. miR-92a could also be used as a valuable indicator for predicting the prognosis of gastric cancer patients.

摘要

背景

据信miR-92a在不同类型肿瘤的诊断和预后中具有重要作用，但由于样本量的原因，其表达的潜在影响仍存在争议。我们进行了荟萃分析，以确定miR-92a是否可作为评估胃癌预后的检测工具。

方法

通过检索Web of Science、PubMed、EMBASE、中国知网、维普（重庆数据库技术）和万方数据库（截至2020年2月更新）进行文献检索。汇总敏感性（SEN）、特异性（SPE）、阳性和阴性似然比（PLR和NLR）、诊断比值比（DOR）和ROC曲线下面积（AUC），以探讨miR-92a的诊断性能。计算miR-92a总体生存（OS）的汇总风险比（HRs）和95%置信区间，以探讨miR-92a的预后性能。

结果

纳入9篇文章，共11项研究。汇总的SEN和SPE分别为0.76和0.79。此外，汇总的PLR和NLR分别为3.7和0.30，汇总的DOR为12。AUC为0.84，表明miR-92a在胃癌检测中具有显著价值。对于miR-92a在胃癌中的预后分析，单变量和多变量数据的OS不良HR分别为1.37和2.01。

结论

本荟萃分析表明，miR-92a可能是检测胃癌的潜在生物标志物。miR-92a也可作为预测胃癌患者预后的有价值指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c04/8447977/a00fa63c23af/j_med-2021-0347-fig006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c04/8447977/8ce7ecd4ecb9/j_med-2021-0347-fig001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c04/8447977/729d2738cc56/j_med-2021-0347-fig002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c04/8447977/44312339cec7/j_med-2021-0347-fig003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c04/8447977/deef1cdcaf47/j_med-2021-0347-fig004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c04/8447977/eead149918ee/j_med-2021-0347-fig005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c04/8447977/a00fa63c23af/j_med-2021-0347-fig006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c04/8447977/8ce7ecd4ecb9/j_med-2021-0347-fig001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c04/8447977/729d2738cc56/j_med-2021-0347-fig002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c04/8447977/44312339cec7/j_med-2021-0347-fig003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c04/8447977/deef1cdcaf47/j_med-2021-0347-fig004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c04/8447977/eead149918ee/j_med-2021-0347-fig005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c04/8447977/a00fa63c23af/j_med-2021-0347-fig006.jpg

相似文献

1
The diagnostic and prognostic value of miR-92a in gastric cancer: A systematic review and meta-analysis.miR-92a在胃癌中的诊断和预后价值：一项系统评价和荟萃分析。
Open Med (Wars). 2021 Sep 16;16(1):1386-1394. doi: 10.1515/med-2021-0347. eCollection 2021.
2
The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis.miR-155 作为肺癌诊断和预后标志物的价值：系统评价与荟萃分析。
BMC Cancer. 2019 Nov 14;19(1):1103. doi: 10.1186/s12885-019-6297-6.
3
Diagnostic and Prognostic Value of miRNAs in Hepatoblastoma: A Systematic Review With Meta-Analysis.微小 RNA 在肝母细胞瘤中的诊断和预后价值：系统评价与荟萃分析。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221087830. doi: 10.1177/15330338221087830.
4
Investigation of MiR-92a as a Prognostic Indicator in Cancer Patients: a Meta-Analysis.miR-92a作为癌症患者预后指标的研究：一项荟萃分析
J Cancer. 2019 Jul 23;10(18):4430-4441. doi: 10.7150/jca.30313. eCollection 2019.
5
MicroRNA-92a as a potential biomarker in diagnosis of colorectal cancer: a systematic review and meta-analysis.MicroRNA-92a作为结直肠癌诊断的潜在生物标志物：一项系统评价和荟萃分析。
PLoS One. 2014 Feb 14;9(2):e88745. doi: 10.1371/journal.pone.0088745. eCollection 2014.
6
MicroRNA-21 and microRNA-30c as diagnostic biomarkers for prostate cancer: a meta-analysis.MicroRNA-21和microRNA-30c作为前列腺癌诊断生物标志物的Meta分析
Cancer Manag Res. 2019 Mar 6;11:2039-2050. doi: 10.2147/CMAR.S189026. eCollection 2019.
7
The Accuracy of Single MicroRNAs in Peripheral Blood to Diagnose Ovarian Cancer: An Updated Meta-Analysis.外周血单个 microRNAs 诊断卵巢癌的准确性：一项更新的荟萃分析。
Dis Markers. 2020 Jan 14;2020:1075942. doi: 10.1155/2020/1075942. eCollection 2020.
8
The diagnostic and prognostic values of microRNA-21 in patients with gastric cancer: a meta-analysis.微小RNA-21在胃癌患者中的诊断和预后价值：一项荟萃分析。
Eur Rev Med Pharmacol Sci. 2017 Jan;21(1):120-130.
9
The Diagnostic and Prognostic Value of miR-200c in Gastric Cancer: A Meta-Analysis.miR-200c 在胃癌中的诊断和预后价值：一项荟萃分析。
Dis Markers. 2019 Apr 4;2019:8949618. doi: 10.1155/2019/8949618. eCollection 2019.
10
Meta-analysis of diagnostic and prognostic value of miR-126 in non-small cell lung cancer.miR-126 在非小细胞肺癌中的诊断和预后价值的荟萃分析。
Biosci Rep. 2020 May 29;40(5). doi: 10.1042/BSR20200349.

引用本文的文献

1
Bibliometric and visualized analysis of global research on microRNAs in gastric cancer: from 2013 to 2023.2013年至2023年全球胃癌微小RNA研究的文献计量学与可视化分析
Front Oncol. 2024 May 10;14:1374743. doi: 10.3389/fonc.2024.1374743. eCollection 2024.
2
Prospects of liquid biopsy in the prognosis and clinical management of gastrointestinal cancers.液体活检在胃肠道癌症预后及临床管理中的前景
Front Mol Biosci. 2024 May 6;11:1385238. doi: 10.3389/fmolb.2024.1385238. eCollection 2024.
3
Non-coding RNAs and gastrointestinal cancers prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies.

本文引用的文献

1
Regulatory Mechanism of MicroRNA Expression in Cancer.癌症中 microRNA 表达的调控机制
Int J Mol Sci. 2020 Mar 3;21(5):1723. doi: 10.3390/ijms21051723.
2
Circulating microRNAs as biomarkers in cancer diagnosis.循环 microRNAs 作为癌症诊断的生物标志物。
Life Sci. 2020 May 1;248:117473. doi: 10.1016/j.lfs.2020.117473. Epub 2020 Feb 27.
3
Exosomal microRNA in peritoneal fluid as a biomarker of peritoneal metastases from gastric cancer.腹水中的外泌体微小RNA作为胃癌腹膜转移的生物标志物
非编码RNA与胃肠道癌症预后：观察性研究的系统评价和荟萃分析的综合评价
Front Oncol. 2023 Jul 20;13:1193665. doi: 10.3389/fonc.2023.1193665. eCollection 2023.
Ann Gastroenterol Surg. 2019 Nov 6;4(1):84-93. doi: 10.1002/ags3.12296. eCollection 2020 Jan.
4
Circulating Extracellular Vesicle MicroRNA as Diagnostic Biomarkers in Early Colorectal Cancer-A Review.循环细胞外囊泡微小RNA作为早期结直肠癌诊断生物标志物的综述
Cancers (Basel). 2019 Dec 23;12(1):52. doi: 10.3390/cancers12010052.
5
No clear choice between Newcastle-Ottawa Scale and Appraisal Tool for Cross-Sectional Studies to assess methodological quality in cross-sectional studies of health-related quality of life and breast cancer.在评估健康相关生命质量和乳腺癌的横断面研究的方法学质量时，Newcastle-Ottawa Scale 和 Appraisal Tool for Cross-Sectional Studies 之间没有明显的选择。
J Clin Epidemiol. 2020 Apr;120:94-103. doi: 10.1016/j.jclinepi.2019.12.013. Epub 2019 Dec 19.
6
MiR-92a Family: A Novel Diagnostic Biomarker and Potential Therapeutic Target in Human Cancers.微小RNA-92a家族：人类癌症中的一种新型诊断生物标志物及潜在治疗靶点
Front Mol Biosci. 2019 Oct 1;6:98. doi: 10.3389/fmolb.2019.00098. eCollection 2019.
7
Plasma exosome-encapsulated microRNA-21 and microRNA-92a are promising biomarkers for the prediction of peritoneal recurrence in patients with gastric cancer.血浆外泌体包裹的微小RNA-21和微小RNA-92a是预测胃癌患者腹膜复发的有前景的生物标志物。
Oncol Lett. 2019 Nov;18(5):4467-4480. doi: 10.3892/ol.2019.10807. Epub 2019 Sep 4.
8
Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.根据肿瘤类型分析乳腺癌中 miR-17-92 簇和 miR-17 家族的差异表达；来自挪威妇女与癌症（NOWAC）研究的结果。
J Transl Med. 2019 Oct 3;17(1):334. doi: 10.1186/s12967-019-2086-x.
9
Investigation of MiR-92a as a Prognostic Indicator in Cancer Patients: a Meta-Analysis.miR-92a作为癌症患者预后指标的研究：一项荟萃分析
J Cancer. 2019 Jul 23;10(18):4430-4441. doi: 10.7150/jca.30313. eCollection 2019.
10
Identification of microRNA-92a and the related combination biomarkers as promising substrates in predicting risk, recurrence and poor survival of colorectal cancer.鉴定微小RNA-92a及相关联合生物标志物作为预测结直肠癌风险、复发和不良生存的有前景指标。
J Cancer. 2019 Jun 2;10(14):3154-3171. doi: 10.7150/jca.30306. eCollection 2019.